Horizon Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Horizon Therapeutics has a total shareholder equity of $5.3B and total debt of $2.6B, which brings its debt-to-equity ratio to 48.2%. Its total assets and total liabilities are $9.3B and $4.0B respectively. Horizon Therapeutics's EBIT is $644.3M making its interest coverage ratio 9.4. It has cash and short-term investments of $2.5B.
Key information
48.2%
Debt to equity ratio
US$2.56b
Debt
| Interest coverage ratio | 9.4x |
| Cash | US$2.48b |
| Equity | US$5.31b |
| Total liabilities | US$3.99b |
| Total assets | US$9.30b |
Recent financial health updates
Recent updates
Horizon pays HemoShear milestone payment under pact to develop gout therapies
Sep 21Horizon Therapeutics announces $500M buyback program
Sep 09Horizon Therapeutics to expand footprint in Ireland
Aug 29Horizon Therapeutics: This Core Biotech Company Is On Sale
Aug 19Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth
Jul 31Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout
Jul 08Financial Position Analysis
Short Term Liabilities: HZNP's short term assets ($3.9B) exceed its short term liabilities ($917.7M).
Long Term Liabilities: HZNP's short term assets ($3.9B) exceed its long term liabilities ($3.1B).
Debt to Equity History and Analysis
Debt Level: HZNP's net debt to equity ratio (1.4%) is considered satisfactory.
Reducing Debt: HZNP's debt to equity ratio has reduced from 219.2% to 48.2% over the past 5 years.
Debt Coverage: HZNP's debt is well covered by operating cash flow (40.7%).
Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (9.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/10 06:43 |
| End of Day Share Price | 2023/10/05 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Horizon Therapeutics Public Limited Company is covered by 24 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Donald Ellis | Avondale Partners |
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |